Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
Status:
Completed
Trial end date:
2020-03-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that the type, number and/or distribution of tumor
metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature
in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore
safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a
basis for subsequent studies in combination with immunotherapies, in particular checkpoint
inhibitors.